NCT05168462View on ClinicalTrials.gov

Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction

PHASE4RecruitingINTERVENTIONAL

Enrollment

776

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions

Cardiogenic ShockMyocardial Infarction

Interventions

DRUG

Reduced noradrenaline use

Reduced noradrenaline by using a lower MAP target

Trial Locations (1)

1105AZ

RECRUITING

Amsterdam UMC, location AMC, Amsterdam

All Listed Sponsors

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT05168462 - Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction | Biotech Hunter | Biotech Hunter